EMLA for newborns is:
**Core Concept**
The use of EMLA (Eutectic Mixture of Local Anesthetics) in newborns raises concerns about the potential toxicity of its components, lidocaine and prilocaine. This question requires an understanding of the pharmacokinetics and pharmacodynamics of local anesthetics in neonates.
**Why the Correct Answer is Right**
EMLA is not recommended for use in newborns because it can cause methemoglobinemia, a condition characterized by elevated levels of methemoglobin in the blood. Methemoglobin has a reduced ability to bind oxygen, leading to tissue hypoxia. The risk of methemoglobinemia is higher in neonates due to their immature metabolic pathways and increased sensitivity to local anesthetics.
**Why Each Wrong Option is Incorrect**
* **Option A:** While EMLA is used to prevent pain in various procedures, its use in newborns is not recommended due to the risk of methemoglobinemia.
* **Option B:** This statement is incorrect, as EMLA is not contraindicated in newborns due to its formulation; rather, it's the potential toxicity of its components that's a concern.
* **Option C:** This is incorrect, as EMLA is not typically used to treat pain in newborns; its use is more commonly associated with minor procedures in adults and children.
**Clinical Pearl / High-Yield Fact**
Newborns are particularly susceptible to the adverse effects of local anesthetics due to their immature liver enzyme systems, which can lead to increased levels of the drug and its metabolites.
**Correct Answer:** D.